Expert: Biogen Is Closing In On The 'Holy Grail' For Biotech Stocks
In this week's episode, Estimize is joined by Joe McCann, a former biotech analyst at CR Intrinsic and the CEO of Slingshot Insights.
In the episode, Joe discusses Biogen Inc (NASDAQ: BIIB)'s new drug, which could be the holy grail for biotech stocks. Leigh and Joe also chat about a hedge fund that seeks to make drug prices cheaper, and wrap things up with a complete earnings overview for the biotech sector.
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.